(Q34953308)

5 August 2017

1 reference

title

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials (English)

1 reference

5 August 2017

main subject

hepatocellular carcinoma

1 reference

resectable hepatocellular carcinoma

inferred from title

1 reference

Jonathan D Schwartz

1

1 reference

5 August 2017

Myron Schwartz

series ordinal

2

1 reference

5 August 2017

John Mandeli

series ordinal

3

1 reference

5 August 2017

Max Sung

series ordinal

4

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Lancet Oncology Commission

5 August 2017

published in

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

593-603

1 reference

5 August 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Long interval between HCV infection and development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Hepatic resection for hepatocellular carcinoma. An audit of 343 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Hepatocellular Carcinoma and Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Postoperative chemoimmunotherapy for the treatment of liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Synthetic retinoids for the secondary prevention of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Clonal Origin of Recurrent Hepatocellular Carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Multiple hepatocellular carcinomas at the early stage have different clonality

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Preoperative chemoradiotherapy for esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900873-2

7 January 2021

10.1016/S1470-2045(02)00873-2

Identifiers

DOI

1 reference

5 August 2017

1 reference